Description: Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. It has a strategic partnership with Aurelius Biotherapeutics LLC to investigate and develop LTX-122 for the veterinary medicine market. The company was founded in 2003 and is based in Oslo, Norway.
Home Page: www.lytixbiopharma.com
Sandakerveien 138
Oslo,
0484
Norway
Phone:
47 95 26 05 12
Officers
| Name | Title |
|---|---|
| Dr. Oystein Rekdal Ph.D. | Co-Founder & CEO |
| Mr. Gjest Breistein M.Sc. | Chief Financial Officer |
| Dr. Gry Stensrud Ph.D. | Chief Technology Officer |
| Dr. Baldur Sveinbjørnsson Ph.D. | Chief Scientific Officer |
| Dr. Andrew Saunders | Chief Medical Officer |
| Dr. Graeme Currie Ph.D. | Chief Devel. Officer |
| Mr. Stephen T. Worsley MBA | Chief Bus. Officer |
Exchange: OL
Country: NO
Currency: Norwegian Krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0782 |
| Price-to-Sales TTM: | 39.8561 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |